Delving into the Latest Updates on Bone Marrow-Derived Mesenchymal Stem Cells(Mayo Clinic) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

BM-MSCs(Mayo Clinic)

Target-

Mechanism

Stem cell replacements

Therapeutic Areas

Skin and Musculoskeletal DiseasesNervous System Diseases

Active Indication

Arthropathy of lumbar facet jointLow Back Pain

Inactive Indication-

Originator Organization

Mayo Clinic

Active Organization

Mayo Clinic

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

A phase 2/3 prospective, multicentre randomized, double-blind trial, comparing intradiscal allogeneic adult BM-MSC therapy and sham-treated controls in subjects withchronic low back pain due to lumbar degenerative disc disease (DDD) unresponsive toconventional therapy - Efficacy of intradiscal injection of BM-MSC in subjects with chronic LBP due to lumbar DDD unrespons

Start Date19 Jun 2018

Sponsor / Collaborator-

100 Clinical Results associated with Bone Marrow-Derived Mesenchymal Stem Cells(Mayo Clinic)

Login to view more data

100 Translational Medicine associated with Bone Marrow-Derived Mesenchymal Stem Cells(Mayo Clinic)

Login to view more data

100 Patents (Medical) associated with Bone Marrow-Derived Mesenchymal Stem Cells(Mayo Clinic)

Login to view more data

273

Literatures (Medical) associated with Bone Marrow-Derived Mesenchymal Stem Cells(Mayo Clinic)

01 Dec 2024·Molecular Biology Reports

Benefits of bone marrow mesenchymal stem cells compared to their conditioned medium in valproic acid-induced autism in rats

Article

Author: Ghafari, Neda ; Pasbakhsh, Parichehr ; Noshadian, Mehrazin ; Zarini, Davood ; Ragerdi Kashani, Iraj ; Asadi-Golshan, Reza ; Zahedi, Elham

BACKGROUNDAutism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by repetitive behaviors, a limited range of activities, and deficiencies in social communications. Bone marrow mesenchymal stem cells (BM-MSCs), which secrete factors that stimulate surrounding microenvironment, and BM-MSCs conditioned medium (BM-MSCs-CM), which contains cell-secreted products, have been speculated to hold potential as a therapy for ASD. This study aimed to compare the therapeutic effects of BM-MSCs and BM-MSCs-CM on behavioral and microglial changes in an animal model of autism induced by valproic acid (VPA).METHODS AND RESULTSPregnant Wistar rats were administered by VPA at a dose of 600 mg/kg at 12.5 days post-conception. After birth, male pups were included in the study. At 6 weeks of age, one group of rats received intranasal administration of BM-MSCs, while another group received BM-MSCs-CM. The rats were allowed to recover for 2 weeks. Behavioral tests, quantitative real-time polymerase chain reaction (qRT-PCR), and immunohistochemistry were performed. Both BM-MSCs and BM-MSCs-CM administration significantly improved some behavioral deficits. Furthermore, these treatments notably reduced Iba-1 marker associated with microgliosis. Additionally, there was a significant reduction in the expression of pro-inflammatory cytokines IL-1β and IL-6, and an increase in the levels of the anti-inflammatory cytokine IL-10 in rats administered by BM-MSCs and BM-MSCs-CM.CONCLUSIONSPost-developmental administration of BM-MSCs and BM-MSCs-CM can ameliorate prenatal neurodevelopmental deficits, restore cognitive and social behaviors, and modulate microglial and inflammatory markers. Results indicated that the improvement rate was higher in the BM-MSCs group than BM-MSCs-CM group.

01 Oct 2024·Archives of Oral Biology

Bone marrow derived mesenchymal stem cells restored GLUT1 expression in the submandibular salivary glands of ovariectomized rats

Article

Author: El Shahawy, Maha ; Badawy, Mohamed ; El-Badawy, Menna Abdulqader

OBJECTIVELoss of ovarian function in menopause is commonly associated with salivary gland dysfunction. The aim is to study the possible therapeutic effect of bone marrow mesenchymal stem cells (BM-MSCs) on the altered structure of the submandibular salivary glands (SMGs) of ovariectomized rats.DESIGNTwenty-four female, adult, Wistar rats were used and distributed into three groups (8 rats/group). The control group included sham-operated rats. The ovariectomized group consisted of rats with removed ovaries. The third group consisted of ovariectomized rats received injections, via tail, of MSCs extracted from bone marrow of 3-weeks-old rat hind limb (BM-MSC group). Four weeks after BM-MSC transplantation, the bone mineral density (BMD) of the femur was detected. The SMG was dissected and processed for histological, immunohistochemical, and histomorphometric analyses.RESULTSThe ovariectomized rats depicted low BMD in the femur. The SMG acini revealed atrophy. The ductal and acinar cells depicted vacuolization and abnormal nuclear histology. GLUT1 immunostaining was decreased in SMG ducts. The BM-MSC group resumed the normal SMG histology and GLUT1 immunolabelling.CONCLUSIONSBM-MSC therapy restored the normal SMG structure and GLUT1 immunostaining in the treated ovariectomized rats, suggesting improved glucose transporting function.

01 Sep 2024·Archives of Oral Biology

Locally injected bone marrow-derived mesenchymal stem cells reverts the histopathological changes in the tongue of carbimazole-induced hypothyroidism of male rats

Article

Author: Mahmoud, Hebatallah ; Badawy, Mohamed ; El Shahawy, Maha ; Mohammed, Sahar Abdel-Nasser

OBJECTIVETo decipher the role of locally injected bone marrow mesenchymal stem cells (BM-MSCs) in the tongue of hypothyroid rats.DESIGNA total 24 male Wister rats were utilized and allocated into 3 groups (n = 8). As for the control group, rats received distilled water via oral gavage. In the hypothyroid group, rats administered carbimazole 5 mg/ 250 g/ day for 6 successive weeks, for hypothyroidism induction. The BM-MSC treated hypothyroid group (BM-MSC group); hypothyroid rats received local injection of 0.5 million BM-MSCs in tongue. Six weeks after BM-MSC injection, tongue samples were processed for Hematoxylin and eosin (H and E) staining, Ki67-immunohistochemistry and histomorphometric analysis.RESULTSThe hypothyroid group revealed degenerative alterations in the lingual papillae, and apparent thinning of the inferior lingual epithelium compared to their controls. Tongues of the BM-MSC group depicted restoration of the normal tongue histology. The Ki67 immunoreaction was apparently decreased in the lingual epithelium of hypothyroid group compared to their controls, however the BM-MSC group regained Ki67 immunostaining.CONCLUSIONOur data suggest that administration of BM-MSCs rescued the degenerative changes in the lingual mucosa and one of the possible underlying mechanisms could be the restoration of cellular proliferation in the lingual epithelium.

100 Deals associated with Bone Marrow-Derived Mesenchymal Stem Cells(Mayo Clinic)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Arthropathy of lumbar facet joint	Phase 2	US	Mayo Clinic	03 Nov 2023
Low Back Pain	Phase 2	US	Mayo Clinic	03 Nov 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


P120 (EBMT2020)	Not Applicable	Steroid Refractory Graft Versus Host Disease	18	WJ-MSC	(jmkcdsuqzk) = bihlmknqub velbtmrank (pbxhnaucxx )	Positive	29 Aug 2020
				BM-MSC	(jmkcdsuqzk) = ykfzzxkuqa velbtmrank (pbxhnaucxx )